After stratifying COVID-19 patients into ARDS and non-ARDS groups, higher plasma NfL levels were observed in the ARDS compared to the non-ARDS group (33.8 [18.1–72.2] and 17.8 [10.2–27.6] pg/mL, respectively, p = 0.0005) (Figure 2B). This evidence concerns the gene NEFL and acute respiratory distress syndrome.